Shots:

• Sanofi to receive ~$353M including $2.25M up front and remaining as development- regulatory and commercial milestones as well as royalties on WW net sales of programs
• GBT gets exclusive WW rights to two early-stage research programs in SCD. One program pursues a novel anti-sickling mechanism and the other leverages a new approach to reduce inflammation and oxidative stress
• GBT will conduct all research- development- regulatory and commercialization activities globally. The addition of novel programs will complement GBT’s existing pipeline and support the company’s strategy to address SCD

 ­ Ref: GlobeNewswire | Image: Crunch Base